RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 21 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 21

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Chao-Yang Hospital首都医科大学附属北京朝阳医院BeijingHospital page
  2. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  3. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  4. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  5. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  6. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  7. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  8. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  9. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  10. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  11. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  12. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  13. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  14. Study siteQingdao Central Hospital康复大学青岛中心医院QingdaoHospital page
  15. Study siteRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
  16. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  17. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  18. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  19. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  20. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  21. Study siteXinqiao Hospital, Army Medical University陆军军医大学第二附属医院(新桥医院)ChongqingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05294731, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Highly effective method of birth control during study treatment period, and for ≥ 30 days after the last dose of the study drug

    Inclusion criterion 6

    Prior autologous stem cell transplant unless ≥ 3 months after transplant, prior chimeric cell therapy unless ≥ 6 months after cell infusion, prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug

    Exclusion criterion 4

  3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

    Inclusion criterion 2

  4. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05294731, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Inclusion Criteria

  • Provision of signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
  • Adequate hematologic, coagulation, renal, pancreatic, and hepatic function, and measurable disease according to disease-specific criteria, as applicable
  • Phase 1: Confirmed diagnosis of R/R Marginal Zone Lymphoma (MZL), Follicular Lymphoma (grade 1-3a), Waldenström Macroglobulinemia (WM), non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), Richter's transformation to DLBCL, MCL, or CLL/SLL
  • Phase 2: Confirmed diagnosis of MCL, or CLL/SLL
  • Highly effective method of birth control during study treatment period, and for ≥ 30 days after the last dose of the study drug

Key Exclusion Criteria

  • Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer
  • Require ongoing systemic treatment for any other malignancy or systemic corticosteroid treatment
  • Current or history of central nervous involvement
  • Prior autologous stem cell transplant unless ≥ 3 months after transplant, prior chimeric cell therapy unless ≥ 6 months after cell infusion, prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Quoted from ClinicalTrials.gov, NCT05294731, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05294731, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05294731